Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 7, 2007 Brian Lawler	Are You Ignoring the Most Exciting Stocks? Never considered drug stocks? You're missing some of the market's best investments.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool February 12, 2007 Brian Lawler	I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
The Motley Fool June 6, 2008 Brian Richards	Roundtable: Dow 10,000? After topping the 14,000 mark last October, the Dow now sits around 12,300. What should investors make of the drop? Where is the market headed from here?
The Motley Fool September 16, 2008 Brian Orelli	Is Pharma Still a Safe Investment? People still have to take their medicine. Health care, like food, is something that just isn't very discretionary. And that bodes well for drugmakers. Really.
The Motley Fool February 14, 2008 Timothy M. Otte	Could These 3 Stocks Beat the Recession, Again? Let's look at three large-cap stocks that beat the 2001 recession: Proctor & Gamble... Archer Daniels Midland... Johnson & Johnson...
Inc. May 1, 2002 Kenneth Klee	The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...
The Motley Fool September 30, 2008 Brian Lawler	Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's.
The Motley Fool May 26, 2006 S.J. Caplan	Happy Birthday, Dow! The Dow Jones Industrial Average turns 110 years old today.
The Motley Fool December 30, 2008 Dan Caplinger	Can You Beat Index Funds in 2009? Get the right mix in your investments.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
The Motley Fool February 6, 2008 Sham Gad	Don't Believe Everything You Hear Contrary to popular media opinion, not every single recession is bad for the investor.
The Motley Fool March 3, 2008 Brian Lawler	Watching Big Pharmas' Investments Investors need to take a look at large drugmakers' balance sheets.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool October 19, 2009 Selena Maranjian	Is Your Index Fund Behaving Stupidly? You don't have to settle for investment allocations in your funds that you don't like.
The Motley Fool April 30, 2007 John Rosevear	Why 13,000 Doesn't Matter How much should we care about the grand old Dow? Is this classic index really worth the attention it gets?
The Motley Fool November 10, 2009 Alex Dumortier	The Dow's New High Signals Change Is the shift to quality beginning? This high could be symbolic of a shift in the market away from lower-quality/higher-risk names to higher-quality stocks.
Investment Advisor April 2010 Vaughan Scully	The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform There are about two dozen exchange traded funds that offer a wide variety of exposures to the healthcare sector, including broad-based, global, and leveraged ETFs, as well as those targeting individual industries.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool January 25, 2011 Eric Dutram	Tuesday's ETF to Watch: iShares Dow Jones U.S. Health Care Index Fund (IYH) The health-care sector has stagnated in recent weeks -- what does that mean for these ETFs?
The Motley Fool October 29, 2011 Robert Eberhard	How the Dow's Latest Picks Have Fared We take a closer look at the junior stocks on the Dow Jones Industrial Average.
The Motley Fool February 12, 2007 Dan Caplinger	Do the Averages Matter? In general, although news of record highs among various stock market indices can make for a nice headline or leading story on the nightly news, market averages aren't too important to most investors.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
The Motley Fool January 3, 2012 Anand Chokkavelu	Why the Dow Exploded Out of the Gate Today The market came out swinging in 2012, with all three major indices up more than 2% in early trading before finishing up around a percent and a half.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool February 17, 2011 Brian Orelli	What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate.
InternetNews June 12, 2009 Paul Shread	Technical Analysis: S&P Stalls at a Big Level The S&P 500 is stuck at a big level here, but at least it's hanging in there.
The Motley Fool January 14, 2011 Dan Caplinger	Your Index Fund Is Making a Bad Investment Funds have to do what the indexes they track do.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool March 22, 2005	Beyond the S&P 500 Index investors have more choices than just the S&P 500.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
Financial Planning June 1, 2005 Craig L. Israelsen	Three's Not a Crowd How passive fund investors can get the best exposure to the whole U.S. market.
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.
The Motley Fool January 17, 2012 Anand Chokkavelu	Why the Dow Jumped Out of the Gate Today Breaking down the market.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool February 28, 2011 David Williamson	Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Financial Planning October 1, 2011 Craig L. Israelsen	Multiply Returns by Dividing Gaining exposure to U.S. stocks by using three equally weighted index funds produced better performance than a single mega-market index fund during the Lost Decade of 2001 to 2010.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
InternetNews January 26, 2010	Technical Analysis: Dow Remains the Big Problem A big level on the Dow sparks a stock market tumble.
The Motley Fool August 3, 2010 Eric Dutram	Tuesday's ETF to Watch: Basic Materials ETF (IYM) What to keep your eyes on today.
The Motley Fool December 14, 2009 Rick Aristotle Munarriz	Rumble in the S&P 500 Jungle By the end of the trading week, Visa and Mead Johnson Nutrition will be added to the S&P 500, where they will take the place of Ciena and MBIA
The Motley Fool April 25, 2011 Cindy Johnson	It's Time to Sell Your Small-Cap Stocks Large-cap valuations are unusually attractive.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool November 16, 2006 Selena Maranjian	The Best ETF for 2007: iShares Dow Jones Select Dividend Wondering what exactly is in the iShares Dow Jones Select Dividend Index? Wonder no more. It invests in the 100 (or so) highest-yielding companies in the Dow Jones U.S. Total Market Index.